Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.
about
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisMultiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiencyThe evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimismIdentification of novel drugs to target dormant micrometastasesFive-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells.Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stressDiscovery of modulators of HIV-1 infection from the human peptidome.Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studiesHDAC inhibitors in kidney development and disease.Preclinical screening methods in cancer.Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.Chemistry and Biology of Resveratrol-Derived Natural ProductsThe development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Using computational strategies to predict potential drugs for nasopharyngeal carcinoma.BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030.Design, Synthesis and Biological Activity Evaluation of S-Substituted 1-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal Cancer
P2860
Q24288687-D470F395-E287-4881-B872-371185F9C46AQ26827999-B4845FD1-AC7B-4A29-8BBF-D4BC6FC51E2AQ28087427-4D4E0875-B336-4D81-9239-F7533BF1A8A8Q28394296-C34C5195-A9FC-4511-BD17-6D31C53726A0Q33898926-53F8E7C4-2BDD-4BB0-9DDF-061B917C8869Q35103873-AAC94A44-D93B-499A-90A2-3226B3A90EDEQ35222585-7059A935-AC5E-49F0-891E-19D902C33C7CQ35653603-C806DECE-50CE-41BE-A9A2-180C17B2E051Q36740696-FB7C2A8D-5275-4782-987D-783F6E7F12FDQ37115414-5F6E1520-833D-466D-B179-3327825DB9B3Q37311933-0332ABB3-C363-4082-8AF1-4604AAE4F1D7Q37660292-23041E3E-1D67-49DA-940E-0771D303114EQ38401947-60EF5CB6-14C9-4900-A15B-3EC36115B3AFQ38907580-4238E6EE-5668-474F-B993-267D0C2E5126Q39095740-6EED3CD5-0A07-4B44-87EB-659469725CFBQ42540751-B74DC5F4-38D9-49A0-9BA2-52A943A5168AQ50200634-C5FFD59B-D9F7-4C53-B978-451467180B2DQ57167787-7860ADAC-5A33-446B-8B92-4AC09CE06A37
P2860
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Preclinical predictors of anti ...... required of candidate agents.
@ast
Preclinical predictors of anti ...... required of candidate agents.
@en
type
label
Preclinical predictors of anti ...... required of candidate agents.
@ast
Preclinical predictors of anti ...... required of candidate agents.
@en
prefLabel
Preclinical predictors of anti ...... required of candidate agents.
@ast
Preclinical predictors of anti ...... required of candidate agents.
@en
P2093
P2860
P356
P1476
Preclinical predictors of anti ...... required of candidate agents.
@en
P2093
Basil Rigas
Ka-Wing Cheng
P2860
P304
P356
10.1124/JPET.112.191957
P407
P577
2012-03-23T00:00:00Z